Replies to post #229761 on Biotech Values

[DewDiligence]

Re: Secondary bacterial pneumonia

A private company is trying to outdo PFE and MRK in the very large market for vaccines against pneumococcal pneumonia, which has become even more relevant during the COVID-19 outbreak:

https://endpts.com/sutrovax-lands-another-100m-in-upstart-quest-against-pfizers-blockbuster-prevnar-13/

See #msg-154439687 for related info.

[biocqr]

COVID-19 patients who were previously vaccinated with Prevnar 13 and/or Pneumovax should have a lower risk of contracting (or dying from) secondary bacterial pneumonia.

I haven't found any meaningful data as to the prevalence of secondary bacterial/pneumonia infections along with COVID-19. Have you seen any confirmed cases?

[dewophile]

If true then perhaps Prevnar 13 use should be extended to healthcare workers and other at risk populations
I qualify based on age but unfortunately have not gotten it